Aptamers Generated from Cell-SELEX for Molecular Medicine: A Chemical Biology Approach

被引:651
作者
Fang, Xiaohong [1 ]
Tan, Weihong [2 ,3 ,4 ,5 ]
机构
[1] Chinese Acad Sci, Inst Chem, Key Lab Mol Nonostruct & Nonotechnol, Beijing Natl Lab Mol Sci, Beijing 100190, Peoples R China
[2] Univ Florida, Genet Inst, Dept Chem, Gainesville, FL 32611 USA
[3] Univ Florida, Genet Inst, Dept Physiol & Funcl Gen, Gainesville, FL 32611 USA
[4] Univ Florida, McKnight Brain Inst, Gainesville, FL 32611 USA
[5] Hunan Univ, Coll Chem & Chem Engn, Ctr Biomed Engn, Key Lab Chemobiosensing & Chemometr, Changsha 410082, Hunan, Peoples R China
关键词
PROSTATE-CANCER CELLS; TUMOR-CELLS; SYSTEMATIC EVOLUTION; LIVE CELLS; CONJUGATED NANOPARTICLES; EXPONENTIAL ENRICHMENT; PHOTODYNAMIC THERAPY; RNA MOLECULES; IN-VIVO; RECOGNITION;
D O I
10.1021/ar900101s
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Molecular medicine is an emerging field focused on understanding the molecular basis of diseases and translating this information into strategies for diagnosis and therapy. This approach could lead to personalized medical treatments. Currently, our ability to understand human diseases at the molecular level is limited by the lack of molecular tools to identify and characterize the distinct molecular features of the disease state, especially for diseases such as cancer. Among the new tools being developed by researchers including chemists, engineers, and other scientists is a new class of nucleic add probes called aptamers, which are ssDNA/RNA molecules selected to target a wide range of molecules and even cells. In this Account, we will focus on the use of aptamers, generated from cell-based selections, as a novel molecular tool for cancer research. Cancers originate from mutations of human genes. These genetic alterations result in molecular changes to diseased cells, which, in turn, lead to changes in cell morphology and physiology. For decades, clinicians have diagnosed cancers primarily based on the morphology of tumor cells or tissues. However, this method does not always give an accurate diagnosis and does not allow clinicians to effectively assess the complex molecular alterations that are predictive of cancer progression. As genomics and proteomics do not yet allow a full access to this molecular knowledge, aptamer probes represent one effective and practical avenue toward this goal. One special feature of aptamers is that we can isolate them by selection against cancer cells without prior knowledge of the number and arrangement of proteins on the cellular surface. These probes can identify molecular differences between normal and tumor cells and can discriminate among tumor cells of different classifications, at different disease stages, or from different patients. This Account summarizes our recent efforts to develop aptamers through cell-SELEX for the study of cancer and apply those aptamers in cancer diagnosis and therapy. We first discuss how we select aptamers against live cancer cells. We then describe uses of these aptamers. Aptamers can serve as agents for molecular profiling of specific cancer types. They can also be used to modify therapeutic reagents to develop targeted cancer therapies. Aptamers are also aiding the discovery of new cancer biomarkers through the recognition of membrane protein targets. Importantly, we demonstrate how molecular assemblies can integrate the properties of aptamers and, for example, nanoparticles; or microfluidic devices, to improve cancer cell enrichment, detection and therapy.
引用
收藏
页码:48 / 57
页数:10
相关论文
共 53 条
  • [1] From combinatorial chemistry to cancer-targeting peptides
    Aina, Olulanu H.
    Liu, Ruiwu
    Sutcliffe, Julie L.
    Marik, Jan
    Pan, Chong-Xian
    Lam, Kit S.
    [J]. MOLECULAR PHARMACEUTICS, 2007, 4 (05) : 631 - 651
  • [2] Aptamer-facilitated biomarker discovery (AptaBiD)
    Berezovski, Maxim V.
    Lechmann, Matthias
    Musheev, Michael U.
    Mak, Tak W.
    Krylov, Sergey N.
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (28) : 9137 - 9143
  • [3] Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels - Selective targeting of endothelial regulatory protein pigpen
    Blank, M
    Weinschenk, T
    Priemer, M
    Schluesener, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (19) : 16464 - 16468
  • [4] Aptamers come of age - at last
    Bunka, David H. J.
    Stockley, Peter G.
    [J]. NATURE REVIEWS MICROBIOLOGY, 2006, 4 (08) : 588 - 596
  • [5] RETRACTED: Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase (Retracted Article)
    Cerchia, L
    Ducongé, F
    Pestourie, C
    Boulay, J
    Aissouni, Y
    Gombert, K
    Tavitian, B
    de Franciscis, V
    Libri, D
    [J]. PLOS BIOLOGY, 2005, 3 (04) : 697 - 704
  • [6] Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1
    Chaloin, L
    Lehmann, MJ
    Sczakiel, G
    Restle, T
    [J]. NUCLEIC ACIDS RESEARCH, 2002, 30 (18) : 4001 - 4008
  • [7] Molecular recognition of small-cell lung cancer cells using aptamers
    Chen, Hui William
    Medley, Colin D.
    Sefah, Kwame
    Shangguan, Dihua
    Tang, Zhiwen
    Meng, Ling
    Smith, Josh E.
    Tan, Weihong
    [J]. CHEMMEDCHEM, 2008, 3 (06) : 991 - 1001
  • [8] Aptamer mediated siRNA delivery
    Chu, Ted C.
    Twu, Karen Y.
    Ellington, Andrew D.
    Levy, Matthew
    [J]. NUCLEIC ACIDS RESEARCH, 2006, 34 (10)
  • [9] Aptamer:toxin conjugates that specifically target prostate tumor cells
    Chu, Ted C.
    Marks, John W., III
    Lavery, Laura A.
    Faulkner, Sarah
    Rosenblum, Michael G.
    Ellington, Andrew D.
    Levy, Matthew
    [J]. CANCER RESEARCH, 2006, 66 (12) : 5989 - 5992
  • [10] A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment
    Daniels, DA
    Chen, H
    Hicke, BJ
    Swiderek, KM
    Gold, L
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (26) : 15416 - 15421